COMMUNIQUÉS West-GlobeNewswire

-
RedHill Biopharma Announces Positive End-of-Phase II Meeting with FDA on BEKINDA® for IBS-D
12/09/2018 -
Asterias Provides 24 Month Cohort 2 Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
12/09/2018 -
Pernix Therapeutics Holdings, Inc.’s Subsidiaries File Notice of Appeal in Patent Litigation Concerning Zohydro® ER with BeadTek®
12/09/2018 -
Inivata Strengthens Senior Leadership Ahead of Next Stage of Company Growth
12/09/2018 -
Aleafia Completes Second Harvest with Sale to Licensed Producer Imminent
12/09/2018 -
Cyclacel Pharmaceuticals Appoints Robert J. Spiegel, M.D. to Board of Directors
12/09/2018 -
EyePoint Pharmaceuticals Reports Fiscal 2018 Fourth Quarter & Full Year Financial Results and Highlights Recent Progress
12/09/2018 -
Acarix gains market acceptance in Austria; new customers orders CADScor®System for ruling out Coronary Artery Disease (CAD).
12/09/2018 -
Vital Therapies Announces That Topline Results of VTL-308 Fail to Achieve Primary and Secondary Endpoints of Improvement in Survival
12/09/2018 -
Solon Eiendom ASA – Primary insider notification
12/09/2018 -
Shire plc : Rule 2.9 Announcement
12/09/2018 -
Verona Pharma to Present Expanded Dataset from RPL554 Phase 2b Clinical Trial in COPD at European Respiratory Society International Congress
12/09/2018 -
Shire Granted EU Marketing Authorization for Veyvondi® for Adults With Von Willebrand Disease
12/09/2018 -
Notice of Changes in the Supervisory Council of JSC Olainfarm
12/09/2018 -
DBV Technologies Announces Positive DSMB Review of Part A of Phase III Study in Peanut-Allergic Toddlers
12/09/2018 -
DBV Technologies annonce la revue positive par le DSMB des résultats du premier volet de sa phase III réalisé sur de jeunes enfants allergiques à l'arachide
12/09/2018 -
Novartis survey shows psoriasis patients want treatment effect beyond clear skin
12/09/2018 -
FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events
12/09/2018 -
La FDA va examiner la demande supplémentaire de licence de produit biologique pour Praluent® (alirocumab), solution injectable, en tant que traitement potentiel dans la réduction d'événements cardi...
12/09/2018
Pages